戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 inc metalloprotease whose closest homolog is angiotensin I-converting enzyme.
2  Susceptibility to infection correlated with angiotensin I converting enzyme 2 (ACE2) expression leve
3 encoded residues dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site.
4 ells expressing the SARS-CoV receptor, human angiotensin I converting enzyme 2 (hACE2).
5 valuate transgenic mice expressing the human angiotensin I-converting enzyme 2 (ACE2) receptor driven
6 gain insights into its interactions with the angiotensin I-converting enzyme 2 (ACE2)-solute carrier
7       Previously, we have shown that loss of angiotensin-I converting enzyme 2 (ACE2) promotes the AC
8 e of the most widely studied is the gene for angiotensin I converting enzyme (ACE ).
9 he angiotensin II (Ang II)-breakdown enzyme, angiotensin I converting enzyme (ACE) 2, suggests the im
10 cal use of several therapeutic drugs, mostly angiotensin I converting enzyme (ACE) inhibitors and ang
11  identify peptides with dual antioxidant and angiotensin I converting enzyme (ACE) inhibitory activit
12 shed Amadori ketoses showed moderate to weak angiotensin I converting enzyme (ACE) inhibitory activit
13                                              Angiotensin I converting enzyme (ACE) inhibitory and ant
14 he activity of the peptide inhibitors of the angiotensin I converting enzyme (ACE), and the antiradic
15 othelin 1 (EDN1); we assayed the activity of angiotensin I converting enzyme (ACE), which catalyses t
16       The most hydrolysed sample showed high angiotensin I converting enzyme (ACE)-inhibitory and ant
17 ddition to the extract's capacity to inhibit angiotensin I-converting enzyme (ACE) activity.
18                          Using inhibitors of angiotensin I-converting enzyme (ACE) and CP, we show th
19  fraction of the heart and skeletal muscles, angiotensin I-converting enzyme (ACE) and neutral endope
20 g white, and (ii) evaluate the inhibition of angiotensin I-converting enzyme (ACE) by the obtained hy
21 n expended to determine whether the gene for angiotensin I-converting enzyme (ACE) confers susceptibi
22                The peptide inhibition of the angiotensin I-converting enzyme (ACE) from its default b
23      The A-240T and I/D polymorphisms in the angiotensin I-converting enzyme (ACE) gene are markers o
24                                              Angiotensin I-converting enzyme (ACE) hydrolyzes numerou
25  dipeptidyl peptidase-IV (DPP-IV) (0.62) and angiotensin I-converting enzyme (ACE) inhibitor peptides
26            Part of the beneficial effects of angiotensin I-converting enzyme (ACE) inhibitors are due
27                                              Angiotensin I-converting enzyme (ACE) inhibitors derived
28                           To investigate how angiotensin I-converting enzyme (ACE) inhibitors enhance
29                                              Angiotensin I-converting enzyme (ACE) inhibitors have be
30   To investigate further the relationship of angiotensin I-converting enzyme (ACE) inhibitors to acti
31 es, majority of them were found identical to angiotensin I-converting enzyme (ACE) inhibitors, antiox
32                                          The angiotensin I-converting enzyme (ACE) inhibitory activit
33 hiols content but at the same time increased angiotensin I-converting enzyme (ACE) inhibitory activit
34                                          The angiotensin I-converting enzyme (ACE) inhibitory activit
35 In addition, the effects of digestion on the angiotensin I-converting enzyme (ACE) inhibitory activit
36                                              Angiotensin I-converting enzyme (ACE) inhibitory peptide
37             This study aimed to screen novel angiotensin I-converting enzyme (ACE) inhibitory peptide
38 showed different amino acid compositions and angiotensin I-converting enzyme (ACE) inhibitory potenti
39               We determined the influence of angiotensin I-converting enzyme (ACE) insertion (I)/dele
40            Pedigree analyses have shown that angiotensin I-converting enzyme (ACE) levels are influen
41                                              Angiotensin I-converting enzyme (ACE), one of the centra
42    Although both LFHs <3 kDa showed in vitro angiotensin I-converting enzyme (ACE)-inhibitory activit
43 anti-obesity, immunomodulatory, antioxidant, angiotensin I-converting enzyme (ACE)-inhibitory, anti-m
44 s established for oligopeptides that inhibit angiotensin I-converting enzyme (ACE).
45 ion (D) polymorphism (indel) of the gene for angiotensin I-converting enzyme (ACE).
46 bitory effects against alpha-glucosidase and angiotensin I-converting enzyme (ACE).
47                                              Angiotensin I-converting enzyme (ACE)2, a new component
48                                              Angiotensin I-converting enzyme (ACE, or DCP1) is a zinc
49                                              Angiotensin I-converting enzyme (ACE, peptidyl dipeptida
50 HE to HE continuum is specifically marked by angiotensin-I converting enzyme (ACE) expression.
51 and mechanism of action towards antioxidant, angiotensin-I converting enzyme (ACE) inhibition, and di
52  activity (DPPH), degree of hydrolysis (DH), angiotensin-I converting enzyme (ACE) inhibitory activit
53                                              Angiotensin-I converting enzyme (ACE) is a zinc dipeptid
54                                              Angiotensin-I converting enzyme (ACE) is a zinc metallop
55 egation analysis have shown that circulating angiotensin-I converting enzyme (ACE) levels are influen
56                                              Angiotensin-I converting enzyme (ACE) regulates the leve
57                                              Angiotensin-I converting enzyme (ACE) regulates the reni
58                                              Angiotensin-I converting enzyme (ACE), a two-domain dipe
59 -binding proteins were identified as porcine angiotensin-I-converting enzyme (ACE I) and aminopeptida
60 hey protein hydrolysates (WPHs) obtained had angiotensin-I-converting enzyme (ACE) and dipeptidyl pep
61  work in animals suggests that inhibitors of angiotensin-I-converting enzyme (ACE) protect against ca
62 l phenotype [C1Inh, C4, spontaneous amidase, angiotensin-I-converting enzyme (ACE), aminopeptidase P
63 eutral endopeptidase (NEP, EC 3.4.24.11) and angiotensin-I-converting enzyme (ACE, EC 2.4.15.1), have
64                                              Angiotensin-I-converting enzyme (ACE-I) plays a key role
65 he causes of hypertension is the activity of angiotensin-I converting enzyme (ACEI), making its inhib
66                                              Angiotensin-I-converting enzyme activities were 58 (44-7
67 as associated with a significant decrease in angiotensin I-converting enzyme activity and a small, bu
68  pairs, we identified 91 that had discordant angiotensin I-converting enzyme and glutathione S-transf
69 system gene regions (angiotensinogen, renin, angiotensin I-converting enzyme, and angiotensin II rece
70 nd an insertion/deletion polymorphism of the angiotensin I-converting enzyme gene (ACE) may be relate
71             An insertion polymorphism of the angiotensin-I converting enzyme gene (ACE) is common in
72 These results confirm the association of the angiotensin I-converting enzyme indel with Alzheimer's d
73  or FT was assessed to release peptides with angiotensin-I converting enzyme inhibition (ACEi) and di
74 II type 1 receptor antagonist (AT1RA) and/or angiotensin I converting enzyme inhibitor (ACEI) were in
75 are also less responsive to monotherapy with angiotensin-I converting enzyme inhibitors or angiotensi
76 sk diverse population where monotherapy with angiotensin-I converting enzyme inhibitors or angiotensi
77 y HRV only in the 20 participants using ACE (angiotensin I-converting enzyme) inhibitors.
78  amino groups, GABA content, antioxidant and angiotensin I-converting enzyme inhibitory (ACEI) activi
79 ffect on proteolysis and negatively affected angiotensin I-converting enzyme inhibitory activity of f
80  acids), bioactivity (antioxidant effect and angiotensin I-converting enzyme inhibitory activity), rh
81  sweetness, bitterness and umami, as well as angiotensin-I converting enzyme inhibitory activity.
82 haracteristics, and in vitro antioxidant and Angiotensin-I converting enzyme-inhibitory activities we
83                                              Angiotensin I converting enzyme (kininase II; ACE) inhib
84 eported previously a novel mode of action of angiotensin I-converting enzyme (kininase II; ACE) inhib
85 e N- and C-terminal domains of human somatic angiotensin I converting enzyme (sACE-1) demonstrate dis
86                                Human somatic angiotensin I-converting enzyme (sACE) has two active si
87                                Human somatic angiotensin I-converting enzyme (sACE) is a key regulato
88 nst alpha-glucosidase, pancreatic lipase and angiotensin I-converting enzyme, using in vitro models.
89 xidant activity persisted, and inhibition of angiotensin-I converting enzyme was improved after the d